0001636282-24-000062.txt : 20240905 0001636282-24-000062.hdr.sgml : 20240905 20240905160414 ACCESSION NUMBER: 0001636282-24-000062 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20240903 FILED AS OF DATE: 20240905 DATE AS OF CHANGE: 20240905 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Burrows Scott L CENTRAL INDEX KEY: 0001853327 ORGANIZATION NAME: FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-37722 FILM NUMBER: 241281388 MAIL ADDRESS: STREET 1: C/O ARCUTIS BIOTHERAPEUTICS, INC. STREET 2: 3027 TOWNSGATE ROAD, SUITE 300 CITY: WESTLAKE VILLAGE STATE: CA ZIP: 91361 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Spyre Therapeutics, Inc. CENTRAL INDEX KEY: 0001636282 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 464312787 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 221 CRESCENT STREET STREET 2: BUILDING 23, SUITE 105 CITY: WALTHAM STATE: MA ZIP: 02453 BUSINESS PHONE: 6176515940 MAIL ADDRESS: STREET 1: 221 CRESCENT STREET STREET 2: BUILDING 23, SUITE 105 CITY: WALTHAM STATE: MA ZIP: 02453 FORMER COMPANY: FORMER CONFORMED NAME: Aeglea BioTherapeutics, Inc. DATE OF NAME CHANGE: 20150311 4 1 wk-form4_1725566647.xml FORM 4 X0508 4 2024-09-03 0 0001636282 Spyre Therapeutics, Inc. SYRE 0001853327 Burrows Scott L 221 CRESCENT STREET, BUILDING 23, SUITE 105 WALTHAM MA 02453 0 1 0 0 Chief Financial Officer 0 Common Stock 2024-09-03 4 S 0 18531 28.173 D 116422 D The transaction reported reflects the sale of shares of common stock, par value $0.0001 per share, of the Issuer ("Common Stock") in satisfaction of the Reporting Person's tax liability in connection with the settlement of 33,739 restricted stock units ("RSUs"). This sale was made to satisfy tax withholding obligations through a "sell to cover" transaction and does not represent a discretionary trade made by the Reporting Person. The price reported is a weighted average sale price of the Common Stock. These shares were sold in multiple transactions at prices ranging from $27.72 to $28.18, inclusive. The Reporting Person undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Includes 101,214 RSUs. Each RSU represents a contingent right to receive, upon vesting, one share of Common Stock. The RSUs vest in three equal installments on each of September 1, 2025, 2026 and 2027, subject to the Reporting Person's continued employment with the Issuer. /s/ Heidy King-Jones, as Attorney-in-Fact 2024-09-05